申请人:Shirai Junya
公开号:US20100087418A1
公开(公告)日:2010-04-08
Compounds represented by the general formula (I):
wherein each symbol is as defined in the description [with the proviso that 9-chloro-7-(1,1-dimethylethyl)-2,3,4,5-tetrahydro-1,4-benz-oxazepine and N-[[(5S)-2-oxo-3-(2,3,4,5-tetrahydro-1,4-benz-oxazepin-7-yl)-5-oxazolidinyl]methyl]acetamide are excluded], salts of the same, and prodrugs thereof have selective activation effect on serotonin 5-HT
2C
receptor and are useful as preventive and therapeutic agents for lower urinary tract diseases, obesity, and/or pelvic organ prolapse.
通式(I)所代表的化合物,其中每个符号如描述中所定义[但不包括9-氯-7-(1,1-二甲基乙基)-2,3,4,5-四氢-1,4-苯并噁唑啉和N-[[(5S)-2-氧代-3-(2,3,4,5-四氢-1,4-苯并噁唑啉-7-基)-5-噁唑烷基]甲基]乙酰胺],其盐和前药具有选择性激活5-羟色胺5-HT2C受体的效果,并且可用作预防和治疗下尿路疾病、肥胖症和/或盆腔器官脱垂的药物。